What is Ardelyx's market cap?

Ardelyx (ARDX) has a market capitalization of $1.2B and trades on NASDAQ.

What is Ardelyx's revenue and profitability?

Ardelyx generated $427.7M in trailing twelve-month revenue with a net loss of $58.1M, representing a net margin of -13.6%. Gross margin stands at 92.5%, with free cash flow of -$116.6M. These figures are based on the Q1 2026 filing.

Who are Ardelyx's competitors?

Ardelyx's key competitors include Ironwood Pharmaceuticals, Inc., Bausch Health Companies Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does Ardelyx partner with?

Ardelyx's notable partners include SLR Investment Corp., HealthCare Royalty Partners.

Where is Ardelyx headquartered?

Ardelyx is headquartered in United States of America and employs approximately 267 people. It has been publicly traded since 2014.

Ardelyx

ARDX

Ardelyx is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of first-in-class small molecule therapies.

Market cap

$1.25B+20.4%

Revenue$427.7M+18.2%

Net income-$58.1M+31.6%

Free cash flow-$116.6M-43.7%

EPS (diluted)-$0.24—

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$94.5MBeat by $1.7M EPS-$0.15Miss by $0.02

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$122.4M

EPS estimate-$0.05

Financials

Q1 2026

Income statement

See full

Revenue$94.5M+27.5%

Gross profit$89.7M+45.1%

Operating income-$32.8M+9.8%

Net income-$37.6M+8.6%

EPS (diluted)-$0.15+11.8%

Balance sheet

See full

Cash & equivalents$31.2M+1.3%

Total debt$208.3M+34.3%

Total equity$148.6M+2.0%

Total assets$504.5M+23.0%

Cash flow

See full

Operating cash flow-$32.2M+16.2%

CapEx$69.0K-78.8%

Free cash flow-$32.3M+16.7%

Valuation & ratios

Valuation

See full

Market cap$1.25B+20.4%

Enterprise value$1.43B+25.1%

P/S2.9×+0.3×

Profitability

See full

Gross margin92.5%+7.9pp

Net margin-13.6%—

Returns & leverage

See full

Return on equity-39.5%—

Debt / equity1.4×+0.3×

Current ratio3.5×-0.6×

Segments

By product

See full

IBSRELA$70.1M+57.8%

XPHOZAH$23.3M-0.5%

Non-cash royalty revenue related to the sale of future royalties$695.0K-32.3%

Product supply revenue$354.0K+39.4%

Licensing revenue$51.0K-99.0%

By segment

See full

Reportable Segment$94.5M+27.5%

Competitors

By market cap

AbbVie$453.91B+36.3%

Amgen$203.07B+25.3%

Neurocrine Biosciences$17.7B+34.0%

Bausch Health Companies$1.7B-34.3%

Ardelyx$1.2B+22.1%

Eton Pharmaceuticals, Inc.$1.2B+188%

Ironwood Pharmaceuticals$643.6M+398%

Jaguar Health$802.6K-78.1%

By revenue growth

Eton Pharmaceuticals, Inc.+79.9%

Neurocrine Biosciences+28.6%

Ardelyx+18.2%

Ironwood Pharmaceuticals+13.8%

AbbVie+9.5%

Amgen+9.1%

Bausch Health Companies+8.2%

By net margin

Ironwood Pharmaceuticals28.26%+38.4pp

Neurocrine Biosciences21.55%+8.9pp

Amgen20.96%+3.6pp

AbbVie5.79%-1.5pp

Bausch Health Companies-1.88%-9.1pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Ardelyx-13.58%+9.9pp

Profile

Ardelyx is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of first-in-class small molecule therapies. The company focuses on addressing significant unmet medical needs in gastrointestinal and renal health through its proprietary sodium/hydrogen exchanger 3 (NHE3) inhibitor platform.

Competitive position

Ardelyx maintains a unique position as a provider of first-in-class NHE3 inhibitors, offering a novel mechanism of action compared to traditional secretagogues and phosphate binders.

GeographiesUnited States

Customer segmentsSpecialty healthcare providers, Chronic disease patients, Healthcare systems

Business modelDirect-to-market product sales, Research and development, Licensing and collaborations

SuppliersSmall molecule manufacturing, Clinical research organizations, Raw material suppliers

CustomersSpecialty pharmacies, Wholesale drug distributors, Dialysis clinics, Hospitals

CountryUnited States of America

Listed2014

Employees267.0

CEOMichael G. Raab

SectorHealthcare

IndustryBiotechnology

Websiteardelyx.com

FilingsSEC EDGAR

Ask your AI about Ardelyx.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ardelyx's market cap?: Ardelyx (ARDX) has a market capitalization of $1.2B and trades on NASDAQ.
What is Ardelyx's revenue and profitability?: Ardelyx generated $427.7M in trailing twelve-month revenue with a net loss of $58.1M, representing a net margin of -13.6%. Gross margin stands at 92.5%, with free cash flow of -$116.6M. These figures are based on the Q1 2026 filing.
Who are Ardelyx's competitors?: Ardelyx's key competitors include Ironwood Pharmaceuticals, Inc., Bausch Health Companies Inc., AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does Ardelyx partner with?: Ardelyx's notable partners include SLR Investment Corp., HealthCare Royalty Partners.
Where is Ardelyx headquartered?: Ardelyx is headquartered in United States of America and employs approximately 267 people. It has been publicly traded since 2014.